The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial
Abstract
BACKGROUND: Growth hormone-deficient adults have increased cardiovascular mortality. Growth hormone replacement may affect cardiovascular risk. Inflammation plays an important role in atherosclerosis, and inflammatory markers are predictive of cardiovascular events. OBJECTIVE: To investigate the effect of growth hormone replacement on inflammatory and other cardiovascular risk factors. DESIGN: Randomized, single-blind, placebo-controlled trial. PATIENTS: 40 men with adult-onset growth hormone deficiency. INTERVENTION: Growth hormone or placebo given for 18 months at a dose adjusted for normal serum insulin-like growth factor I level. MEASUREMENTS: Anthropometric, hemoglobin A1c, and central fat values were assessed every 6 months. Levels of glucose, insulin, insulin-like growth factor I, and lipids were measured at 1, 3, 6, 12, and 18 months. C-reactive protein, serum amyloid polypeptide A, inteleukin-6, and lipoprotein(a) levels were determined at baseline and 6 and 18 months. RESULTS: C-reactive protein and inteleukin-6 levels decreased in growth hormone recipients compared with placebo recipients (differences between groups, -1.9 +/- 0.6 mg/L [P = 0.0027] and -1.3 +/- 0.5 ng/L [P = 0.013], respectively). Changes in serum amyloid polypeptide A levels between groups did not reach statistical significance (difference between groups, -2.4 +/- 1.2 mg/L; P = 0.056). Serum cholesterol levels, low-density lipoprotein cholesterol levels, and ratios of total cholesterol to high-density lipoprotein cholesterol decreased in growth hormone recipients in the first 3 months compared with placebo recipients (differences between groups, -0.86 +/- 0.17 mmol/L [-33.2 +/- 6.6 mg/dL] [P < 0.001], -0.63 +/- 0.20 mmol/L [-24.5 +/- 5.9 mg/dL] [P < 0.001], and -0.56 +/- 0.26 [P = 0.040], respectively), but the decrease was not maintained from month 6 to month 18. Lipoprotein(a) levels increased (difference between groups, 22.0 +/- 8.0 mg/L; P = 0.0096). Short-term increases occurred in glucose levels, insulin levels, and insulin-to-glucose ratios (differences between groups, 0.54 +/- 0.16 mmol/L [9.6 +/- 2.8 mg/dL] [P = 0.0018], 37.9 +/- 9.6 pmol/L [P < 0.001], and 6.0 +/- 1.8 [P = 0.0025], respectively), but only the increase in glucose level was maintained over the long term (difference between groups, 0.56 +/- 0.17 mmol/L [10.0 +/- 3.1 mg/dL]; P = 0.0026). Hemoglobin A1c values did not change. Truncal fat-to-total fat ratios decreased (difference between groups, -0.018 +/- 0.007; P = 0.0087). CONCLUSIONS: Long-term growth hormone replacement in men reduces levels of inflammatory cardiovascular risk markers, decreases central fat, and increases lipoprotein(a) and glucose levels without affecting lipid levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the development of new cancers and new-onset diabetes are of concern, the safety profile for GH treatment (using appropriate replacement doses) appears favorable in long-term surveillance studies (174).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [174]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,357
Koenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,964
Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.98.8.731 · Cited by 1,642
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.3.230 · Cited by 1,478
Self-citationPremature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Self-citation
Research works printed but not linked: 13
- Pfeifer M, 1999, J Clin Endocrinol Metab, 84, 453
- De Boer H, 1992, J Clin Endocrinol Metab, 75, 833
- Weaver JU, 1995, J Clin Endocrinol Metab, 80, 153
- Cuneo RC, 1998, J Clin Endocrinol Metab, 83, 107
- Bengtsson BA, 1993, J Clin Endocrinol Metab, 76, 309
- Beshyah SA, 1995, J Clin Endocrinol Metab, 80, 356
- Hwu CM, 1997, J Clin Endocrinol Metab, 82, 3285
- Borson-Chazot F, 1999, J Clin Endocrinol Metab, 84, 1329
- Baum HB, 1998, J Clin Endocrinol Metab, 83, 3184
- Hadigan C, 1999, J Clin Endocrinol Metab, 84, 1932
- Serri O, 1999, J Clin Endocrinol Metab, 84, 58
- 10.1001/jama.1993.03500230097036 · DOI · Paper page
- Attanasio AF, 1997, J Clin Endocrinol Metab, 82, 82
Cited by
Ridker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Sarcopenic obesity and inflammation in the InCHIANTI study
Schrager, M. A., Metter, E. J., Simonsick, E., Ble, A., Bandinelli, S., Lauretani, F., & Ferrucci, L. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00627.2006 · Cited by 594
Estrogen Regulation of Growth Hormone Action
Leung, K.-C., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 542
Metadata
- Authors
- Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Sesmilo, Gemma
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2000-07-18
- Volume
- 133
- Issue
- 2
- Pages
- 111-122
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2042102742
- Semantic Scholar
- 35d4bb788c981e6edd0577574356d263132bfc91
- Cited by
- 257
- References
- 68
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 2 · 2022: 7 · 2021: 3 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 10 · 2014: 9 · 2013: 10 · 2012: 13
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32dk008783-01a1)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-08783)
- National Center for Research Resources (M01RR001066, RR-1066)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- growth hormone replacement therapy, adult-onset growth hormone deficiency, cardiovascular risk factors, inflammation, C-reactive protein, interleukin-6, lipoprotein(a), insulin-like growth factor I, lipid profile, LDL cholesterol, cardiovascular mortality, men, atherosclerosis, central fat, insulin resistance, HbA1c
- MeSH terms
- Adipose Tissue, Adult, Serum Amyloid A Protein, Analysis of Variance, Anthropometry, Blood Glucose, C-Reactive Protein, Cardiovascular Diseases, Humans, Inflammation, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Placebos, Risk Factors, Interleukin-6, Single-Blind Method, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial. https://app.cochat.ai/papers/10.7326/0003-4819-133-2-200007180-00010
- The paper
- Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2000). Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-133-2-200007180-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.